JP2021167350A - Skin external composition - Google Patents

Abstract

To provide a skin external composition that is effective in improving symptoms of the brachial outer part, particularly the keratinization of the brachial outer part, particularly lichen pilaris.SOLUTION: A skin external composition for application to the brachial outer part, contains (A) urea, (B) an antiinflammatory agent, and (C) at least one selected from the group consisting of an amino acid, alkanolamine, and a salt thereof. The composition can be suitably used for softening keratin of the brachial outer part, particularly, for preventing, improving, or treating lichen pilaris.SELECTED DRAWING: None

Description

The present invention relates to external skin compositions used as pharmaceuticals, quasi-drugs, or cosmetics.

Keratosis pilaris, a lumpy, rough symptom on the outside of the upper arm, is a common symptom in young women and is a very worrisome symptom when wearing clothing that exposes the upper arm. Keratosis pilaris is a symptom in which the inside of the pores on the outer side of the upper arm is filled with keratin, and the keratin rises to the epidermis to form papules, which is known to be a common symptom in puberty. In addition, although the cause of keratosis pilaris has not been fully elucidated, the genetic predisposition is also considered to be one of the causes because of the large number of familial onsets.
Conventionally, as a medicine for treating keratosis pilaris, an ointment containing urea as an active ingredient in anticipation of a water retention effect in the stratum corneum and an ointment containing salicylic acid and petrolatum as active ingredients in anticipation of a keratin softening effect. Etc. are widely used.
However, there is a need for the development of a more useful external composition for skin that exhibits a satisfactory improving effect on keratosis pilaris.

In addition, urea has been added with the expectation of effects such as skin moisturizing, penetration assistance, rough skin improvement, skin softening, or cell activation, and dipotassium glycyrrhizinate and glycine have been added so as not to be irritating to the skin. A safe emulsified composition is also known (Patent Document 1). However, Patent Document 1 only teaches that the irritation caused by urea is suppressed, and does not mention keratosis pilaris.

Japanese Unexamined Patent Publication No. 2005-60230

An object of the present invention is to provide a composition for external use on the skin, which is excellent in improving the symptoms of the lateral part of the upper arm, particularly the keratinization of the lateral part of the upper arm, particularly keratosis pilaris.

The present inventor has repeated research to solve the above-mentioned problems, and a composition containing (A) urea, (B) an anti-inflammatory agent, and (C) amino acids and / or alkanolamines has keratinized the skin. Among them, it was found that in keratosis pilaris on the outer part of the upper arm, especially in the pores on the outer part of the upper arm, keratosis pilaris increases the amount of keratin water, softens the keratin, and shows a remarkable effect on its improvement. rice field.

The present invention has been completed based on the above findings, and provides the following external composition for skin.
Item 1. External composition for application to the lateral part of the upper arm containing at least one selected from the group consisting of (A) urea, (B) anti-inflammatory agent, and (C) amino acid, alkanolamine, and salts thereof. thing.
Item 2. Item 2. The external composition for skin according to Item 1, which is used for softening the keratin on the outer side of the upper arm.
Item 3. Item 2. The external composition for skin according to Item 1 or 2, which is used for preventing, ameliorating, or treating a rough, lumpy, or lumpy symptom on the outer side of the upper arm.
Item 4. Item 6. The external composition for skin according to any one of Items 1 to 3, which is used for preventing, ameliorating, or treating keratosis pilaris.
Item 5. (B) The item according to any one of Items 1 to 4, wherein the anti-inflammatory agent is at least one selected from the group consisting of glycyrrhizinic acid, glycyrrhetinic acid, stearyl glycyrrhetinate, allantoin, epsilon aminocaproic acid, and salts thereof. Skin external composition.
Item 6. (B) The composition for external use on the skin according to Item 5, wherein the anti-inflammatory agent is at least one selected from the group consisting of glycyrrhizic acid, allantoin and salts thereof.
Item 7. Item (C) is at least one selected from the group consisting of neutral amino acids, acidic amino acids, alkanolamines having 1 to 3 alkanols having 2 to 3 carbon atoms, and salts thereof. The external composition for skin according to any one of.
Item 8. Item 2. The external composition for skin according to Item 7, wherein the component (C) is at least one selected from the group consisting of glycine, triethanolamine, diisopropanolamine and salts thereof.
Item 9. (A) The composition for external use on the skin according to any one of Items 1 to 8, wherein the urea content is 5% by weight or more based on the whole composition.
Item 10. (B) The composition for external use on the skin according to any one of Items 1 to 9, wherein the content of the anti-inflammatory agent is 0.01% by weight or more based on the whole composition.
Item 11. (C) Any of Items 1 to 10, wherein the content of at least one selected from the group consisting of amino acids, alkanolamines, and salts thereof is 0.01% by weight or more based on the total composition. The composition for external use on the skin according to.
Item 12. Item 2. The composition for external use on the skin according to any one of Items 1 to 11, which is an oil-in-water emulsified composition.

The external composition for skin of the present invention containing urea, an anti-inflammatory agent, and amino acids and / or alkanolamines is keratinized on the outer side of the upper arm, particularly in the pores on the outer side of the upper arm. It is highly effective in preventing, ameliorating, or treating keratosis pilaris. Specifically, the water content of the keratin on the outer side of the upper arm can be increased to soften the keratin. Visually, it is effective in preventing, ameliorating, or treating a lumpy, lumpy, or rough condition on the lateral side of the upper arm.

More specifically, urea has a moisturizing effect and a skin softening effect, and is therefore effective in softening the keratin of the skin. In addition, anti-inflammatory agents are expected to have an effect of improving inflammation associated with keratinization. In addition, amino acids and alkanolamines are also known to act as stabilizers for pharmaceuticals, and are expected to contribute to the effects of urea and anti-inflammatory agents. However, for the stratum corneum that is widely thickened on the skin surface such as elbows, knees, and heels, the combined use of urea, anti-inflammatory agents, and amino acids and / or alkanolamines has a synergistic effect on improving keratinization. Is not recognized at all. On the other hand, for keratinization of the lateral part of the upper arm, when urea, an anti-inflammatory agent, and amino acids and / or alkanolamines are used in combination, a remarkable synergistic effect is observed in improving keratinization due to an increase in water content.
This indicates that the keratinization of the elbows, knees, heels, etc. and the keratinization of the lateral part of the upper arm are significantly different, and the external composition for skin of the present invention is due to the softening of the keratin of the lateral part of the upper arm. It has been shown to be particularly suitable for amelioration, especially the prevention, amelioration, or treatment of keratosis pilaris. Therefore, the external composition for skin of the present invention is suitable for use on the lateral part of the upper arm.

It is a graph which shows the measurement result of the keratin water content in the outer part of the upper arm and the heel of a healthy person (Example 1 and Comparative Examples 1 to 3). It is a graph which shows the measurement result of the keratin water content in the keratosis pilaris of the outer part of the upper arm (Example 1 and Comparative Examples 1 to 3). It is a graph which shows the measurement result of the keratin water content in the outer part of the upper arm and the knee of a healthy person (Example 2 and Comparative Examples 4 to 6). It is a graph which shows the measurement result of the keratin water content in the lateral part of the upper arm and the knee of a healthy person (Example 3 and Comparative Examples 7 to 8). It is a graph which shows the measurement result of the keratin water content in the keratosis pilaris of the outer part of the upper arm (Examples 2 and 3). It is a graph which shows the measurement result of the average volume of the ridge in the keratosis pilaris of the lateral part of the upper arm (Examples 2 and 3). It is a graph which shows the measurement result of the keratin water content in the lateral part of the upper arm and the knee of a healthy person (Example 4 and Comparative Examples 9 to 11). It is a graph which shows the measurement result of the keratin water content in the outer part of the upper arm and the knee of a healthy person (Example 5 and Comparative Examples 12-14). It is a graph which shows the measurement result of the keratin water content in the keratosis pilaris of the outer part of the upper arm (Example 5). It is a graph which shows the measurement result of the average volume of the ridge in the keratosis pilaris of the lateral part of the upper arm (Example 5).

Hereinafter, the present invention will be described in detail.
The external composition for skin of the present invention is a composition containing at least one selected from the group consisting of (A) urea, (B) anti-inflammatory agent, and (C) amino acid, alkanolamine, and salts thereof. It is a composition for application to the outer part of the upper arm.

Urea The urea content is preferably 5% by weight or more, more preferably 7% by weight or more, still more preferably 10% by weight or more, based on the total amount of the composition. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.
The urea content in the composition is preferably 30% by weight or less, more preferably 25% by weight or less, still more preferably 20% by weight or less, based on the total amount of the composition. Within the above range, the composition is less irritating.

Anti-inflammatory agents Anti-inflammatory agents can be classified into steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents based on the difference in basic skeleton, and any of these can be used in the present invention. Among them, a non-steroidal anti-inflammatory drug is preferable in that the effects of the present invention described above can be more reliably exerted.

The non-steroidal anti-inflammatory agent is not particularly limited, and for example, glycyrrhizinic acid, glycyrrhetinic acid, stearyl glycyrrhetinate, allantin, epsilon aminocaproic acid, salicylic acid, methyl salicylate, glycol salicylate, indomethacin, felbinac, ibuprofen, ibuprofen piconol, etc. Examples thereof include ketoprofen, bufexamac, butyl flufenamic acid, bendazac, pyroxicum, suprofen, ufenamate, heparin analogs, azulene, guaiazulene, tranexamic acid, and salts thereof.

The salt of the anti-inflammatory agent may be any pharmaceutically or physiologically acceptable salt, for example, a salt with an inorganic base [for example, an ammonium salt; an alkali metal (sodium, potassium, etc.), an alkaline earth metal (calcium). , Magnesium, etc.), Salts with metals such as aluminum]; Salts with organic bases (eg, salts with organic amines such as methylamine, triethylamine, triethanolamine, morpholine, piperazin, pyrrolidine, tripyridine, picolin, etc.) Inorganic acid salts (eg, hydrochlorides, sulfates, nitrates, hydrobromates, phosphates, etc.); Organic acid salts [eg, monocarboxylates (acetate, trifluoroacetate, butyrate, palmitin) Acids, stearate, etc.), polyvalent carboxylates (fumarate, maleate, succinate, malonate, etc.), oxycarboxylates (lactate, tartrate, citrate, etc.), Organic sulfonates (methane sulfonate, toluene sulfonate, tosylate, etc.), etc.] and the like can be mentioned. Among them, salts with inorganic bases or organic bases are preferable, salts with inorganic bases are more preferable, alkali metal salts or ammonium salts are even more preferable, potassium salts, sodium salts or ammonium salts are even more preferable, and potassium. Salt is particularly preferred.

The non-steroidal anti-inflammatory drug may be, for example, a plant extract such as a citrus extract, a sage extract, or a rosemary extract containing these anti-inflammatory drugs.

Specific examples of preferred anti-inflammatory agents include glycyrrhizinic acid, glycyrrhetinic acid, stearyl glycyrrhetinate, allantoin, and epsilon aminocaproic acid, and salts thereof. Among them, glycyrrhizic acid, glycyrrhetinic acid, stearyl glycyrrhetinate, and allantoin, and salts thereof are preferable, and glycyrrhizic acid, allantoin, and salts thereof are more preferable, glycyrrhizic acid, and salts thereof (for example, dipotassium glycyrrhizinate, glycyrrhizin). (Monoammonium acid, etc.) is particularly preferable.

The anti-inflammatory agent may be used alone or in combination of two or more.

The content of the anti-inflammatory agent is preferably 0.01% by weight or more, more preferably 0.05% by weight or more, still more preferably 0.1% by weight or more, based on the total amount of the composition. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.
The content of the anti-inflammatory agent in the composition is preferably 5% by weight or less, more preferably 2% by weight or less, still more preferably 1% by weight or less, based on the total amount of the composition. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.

The content of the anti-inflammatory agent is preferably 0.001 part by weight or more, more preferably 0.005 part by weight or more, and even more preferably 0.01 part by weight or more with respect to 1 part by weight of urea. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.
The content of the anti-inflammatory agent is preferably 1 part by weight or less, more preferably 0.4 parts by weight or less, and even more preferably 0.2 parts by weight or less with respect to 1 part by weight of urea. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.

Amino Acids / Alkanolamines The external composition of the present invention contains amino acids, alkanolamines, and / or salts thereof. In the present specification, amino acids or salts thereof may be referred to as "amino acids", and alkanolamines or salts thereof may be referred to as "alkanolamines".
Amino acid is a general term for compounds containing an amino group and a carboxyl group in the molecule. Alkanolamine is a general term for amines in which at least one of the hydrocarbon chains bonded to a nitrogen atom has a hydroxyl group.

The type of amino acid is not particularly limited as long as it is pharmaceutically or physiologically acceptable, but specifically, glycine, alanine, β-alanine, valine, leucine, isoleucine, proline, hydroxyproline, phenylalanine, methionine, tryptophan. , Neutral amino acids such as cysteine, cystine, γaminobutyric acid, γaminoβ-hydroxybutyric acid, asparagine, glutamine, serine, threonine, tyrosine; acidic amino acids such as glutamic acid, aspartic acid; Examples include basic amino acids such as creatine.
Among them, preferably neutral amino acids and acidic amino acids, more preferably neutral amino acids, and even more preferably hydrogen atoms or lower alkyls such as glycine, alanine, valine, leucine and isoleucine. Examples include neutral amino acids having a side chain of the group, and even more preferably glycine.

The type of alkanolamine is not particularly limited as long as it is pharmaceutically or physiologically acceptable, but specifically, triethanolamine, monoethanolamine, diethanolamine, 2-amino-2-methylpropanediol, diisopropanol. Amine and the like are exemplified.
Among them, alkanolamines having 1 to 3 alkanols having 2 to 3 carbon atoms, for example, diisopropanolamine, triethanolamine, monoethanolamine and diethanolamine are preferable, and triethanolamine and monoethanol are more preferable. Amines, diethanolamines, and even more preferably triethanolamines.

The salt of the amino acid and the alkanolamine may be any salt that is pharmaceutically or physiologically acceptable, and specifically, it may be a salt similar to that exemplified for the anti-inflammatory agent above.
Further, the amino acid, the alkanolamine and the salt thereof may be in the form of a solvate (for example, a hydrate), and may be in any of d-form, l-form and dl-form. Amino acids are preferably l-form and dl-form, and more preferably l-form.
Amino acids and / or alkanolamines may be used alone or in combination of two or more. Preferably, it contains amino acids.

The content of amino acids and / or alkanolamines is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, still more preferably 0.5% by weight or more, based on the total amount of the composition. .. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.
The content of amino acids and / or alkanolamines in the composition is preferably 10% by weight or less, more preferably 8% by weight or less, still more preferably 5% by weight or less, based on the total amount of the composition. .. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.

The content of amino acids and / or alkanolamines is preferably 0.001 part by weight or more, more preferably 0.005 part by weight or more, and 0.01 part by weight or more with respect to 1 part by weight of urea. Even more preferable. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.
The content of amino acids and / or alkanolamines is preferably 1 part by weight or less, more preferably 0.8 parts by weight or less, still more preferably 0.5 parts by weight or less, based on 1 part by weight of urea. preferable. Within the above range, keratinization on the outside of the upper arm can be sufficiently improved.

pH
The pH of the composition of the present invention is preferably 5.5 or higher, more preferably 6 or higher. Further, 8.5 or less is preferable, and 8 or less is more preferable. Within the above range, the keratinization of the outer side of the upper arm can be sufficiently improved, and the generation of ammonia odor due to the decomposition of urea can be suppressed.

Formulation Form In the external composition of the present invention, urea, an anti-inflammatory agent, and amino acids and / or alkanolamines are usually used in pharmaceutical products, quasi-drugs, or cosmetics, and are pharmaceutically or physiologically acceptable. It can be mixed with a base or carrier and, if necessary, an additive for an external composition to obtain a pharmaceutical, quasi-drug, or cosmetic external composition for skin.

The form of the external composition for skin for pharmaceuticals, quasi-drugs, or cosmetics is not particularly limited, and for example, a liquid agent, a suspending agent, an emulsion, a cream agent, an ointment agent, a gel agent, a liniment agent, a lotion agent, and an agent. Examples include aerosols. These formulations can be manufactured according to or in accordance with the methods described in the 16th revised Japanese Pharmacopoeia General Regulations for Formulations. In addition, it may be in the form of a stick agent or a sheet agent obtained by impregnating a non-woven fabric with a chemical solution. A liquid agent, an emulsion, or a cream agent having high permeability to the keratin and excellent usability is preferable, and a cream agent having excellent urea stability is more preferable.
Specific uses of cosmetics and non-pharmaceutical products are not particularly limited, such as lotions, milky lotions, gels, creams, beauty liquids, sunscreen cosmetics, packs, masks, hand creams, body lotions, and body creams. Basic cosmetics; cleaning cosmetics such as washing pigments, makeup removers, body shampoos, shampoos, rinses, and treatments; makeup cosmetics such as foundations and various colors; bathing agents and the like.

As a base or carrier base or carrier, liquid paraffin, squalane, vaseline, hydrocarbon gel (such as Plastibase), ozokerite, alpha-olefin oligomers, and hydrocarbons such as light liquid paraffin; methylpolysiloxane, crosslinked Methylpolysiloxane, highly polymerized methylpolysiloxane, cyclic silicone, alkyl-modified silicone, cross-linked alkyl-modified silicone, amino-modified silicone, polyether-modified silicone, polyglycerin-modified silicone, cross-linked polyether-modified silicone, cross-linked alkyl polyether-modified Silicones such as silicones, silicone-alkyl chain co-modified polyether-modified silicones, silicone-alkyl chain co-modified polyglycerin-modified silicones, polyether-modified branched silicones, polyglycerin-modified branched silicones, acrylic silicones, phenyl-modified silicones, and silicone resins. Oils; higher alcohols such as setanol, cetostearyl alcohol, stearyl alcohol, and behenyl alcohol; sterols such as cholesterol, phytosterol, and phytosteryl hydroxystearate; jojoba oil, medfoam oil, sunflower oil, grape seed oil, camellia oil, Vegetable oils such as squalane, shea butter, and rice germ oil; animal oils such as lanolin, orange raffy oil, squalane, and horse oil; of ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, cationized guagam, and acetylated hyaluronic acid. Natural polymeric derivatives such as; synthetic polymers such as polyvinylpyrrolidone, carboxyvinyl polymers, and alkyl methacrylate copolymers; Natural Polymers: Isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, pentaerythlit tetra2-ethylhexanoate, jojoba oil, and tri (caprylic / capric acid) glyceryl. Esters such as; dextrin, and polysaccharides such as maltodextrin; ethanol, and lower alcohols such as isopropanol; ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropylate. Glycols such as diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monopropyl ether, diethylene glycol monobutyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, dipropylene glycol monoethyl ether, and dipropylene glycol monopropyl ether. Ethers; polyhydric alcohols such as polyethylene glycol, propylene glycol, 1,3-butylene glycol, glycerin, isoprene glycol, diglycerin, and dipropylene glycol; and aqueous bases such as water.
Among them, polyhydric alcohols, higher alcohols, hydrocarbons, esters, and silicone oils are preferable, and polyhydric alcohols are more preferable. Among the polyhydric alcohols, 1,3-butylene glycol, propylene glycol, isoprene glycol, glycerin, diglycerin, and dipropylene glycol are preferable, and 1,3-butylene glycol, propylene glycol, glycerin, and diglycerin are more preferable. ..
The base or carrier may be used alone or in combination of two or more.

When the external composition for skin of the present invention contains an aqueous base and an oily base, it may be either an oil-in-water type or a water-in-oil type emulsified composition, but it gives a feeling of use when applied to the skin. In terms of excellence, an oil-in-water emulsified composition is preferable. The composition of the present invention stabilizes urea even in an oil-in-water emulsified composition containing a large amount of water (for example, 50% by weight or more, preferably 55% by weight or more with respect to the entire preparation). Since it can be blended, it is possible to suppress the generation of an unpleasant ammonia odor.

Additives The compositions of the present invention include known additives that are added to pharmaceuticals, non-pharmaceutical products, or cosmetics, such as antioxidants, surfactants, and thickeners, as long as the effects of the present invention are not impaired. Agents, preservatives, pH regulators, stabilizers, irritants, preservatives, colorants, fragrances, sequestrants and the like can be added.

Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, sorbic acid, sodium sulfite, ascorbic acid, ascorbic acid derivative, tocopherol, tocopherol derivative, erythorbic acid, and L-cysteine hydrochloride.

Examples of the surfactant include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, penta-2-ethylhexylate diglycerol sorbitan, and tetra-2-ethylhexylate diglycerol sorbitan. Sorbitane fatty acid esters such as; propylene glycol fatty acid esters such as propylene glycol monostearate; polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene Hardened castor oil derivatives such as cured castor oil 60 (HCO-60) and polyoxyethylene hydrogenated castor oil 80; polyoxyethylene monolaurate (20) sorbitan (polysolvate 20), polyoxyethylene monostearate (20) sorbitan. Polyoxyethylene sorbitan fatty acid esters such as (polysolvate 60), polyoxyethylene monooleate (20) sorbitan (polysolvate 80), and polyoxyethylene (20) sorbitan isostearate; polyoxyethylene monopalm oil fatty acid glyceryl; Glycerin alkyl ethers; alkyl glucosides; polyoxyalkylene alkyl ethers such as polyoxyethylene cetyl ethers; amines such as stearylamine and oleylamine; polyoxyethylene / methylpolysiloxane copolymers, lauryl PEG-9 polydimethylsiloxy Silicone surfactants such as ethyl dimethicone and PEG-9 polydimethylsiloxyethyl dimethicone; natural surfactants such as phospholipids, surfactins, and saponins; diethylaminoethylamide stearate, and diethylaminopropylamide stearate, etc. Examples thereof include fatty acid amidamines; alkylamines such as trilaurylamine, dimethylstearylamine, and di-2-ethylhexylamine; and betaine-based amphoteric surfactants such as dimethylaminopropylamide stearate and laurylhydroxysulfobetaine.

Examples of thickeners include guar gum, locust bean gum, carrageenan, xanthan gum, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, alkyl methacrylate copolymer, polyethylene glycol, bentonite, alginic acid, macrogol, and sodium chondroitin sulfate. , Hyaluronic acid, and cellulosic thickeners (methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, etc.) and the like.

Examples of preservatives and preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, and paraoxy. Examples thereof include benzyl benzoate, methyl paraoxybenzoate, phenoxyethanol, benzyl alcohol, chlorobutanol, sorbic acid and salts thereof, chlorhexidine gluconate, alcandiol, and glycerin fatty acid ester.

Examples of the pH adjuster include inorganic acids (such as hydrochloric acid and sulfuric acid), organic acids (such as lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, and sodium succinate), and inorganic bases (potassium hydroxide, etc.). And sodium hydroxide, etc.), and organic bases (triethanolamine, diisopropanolamine, triisopropanolamine, etc.) and the like.

Examples of the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, and bitylhydroxyanisole.

Examples of the irritation reducing agent include licorice extract and sodium alginate.

Examples of the colorant include pigments described in the Legal Dye Handbook (edited by the Japan Cosmetic Industry Association (2004)).

As fragrances, herbal essential oils such as lavender oil, rosemary oil, clarisage oil, thyme oil, bergamot oil and eucalyptus oil, mint essential oils such as peppermint oil, spare mint oil and peppermint oil, orange oil, lemon oil and grapefruit oil. Various essential oils such as citrus essential oils, compounded fragrances and the like can be mentioned.

Examples of the sequestrant include EDTA.

As the additive, one type can be used alone, or two or more types can be used in combination.

Other Active Ingredients The external composition for skin of the present invention contains an active ingredient (physiologically active ingredient or pharmacologically active ingredient) other than urea, an anti-inflammatory agent, an amino acid, and an alkanolamine as long as the effect of the present invention is not impaired. Can be done. Specific examples of the active ingredient include moisturizing ingredients, antibacterial or bactericidal ingredients, vitamins, peptides or derivatives thereof, amino acid derivatives, cell activating ingredients, antiaging ingredients, blood circulation promoting ingredients, keratin softening ingredients, whitening ingredients, etc. Convergent components, UV protection components, and the like can be mentioned.

Moisturizing ingredients include, for example, polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol, dipropylene glycol, sorbitol, xylitol, erythritol, and diglycerin; such as glucose, maltose, and trehalose. Sugars; sodium hyaluronate, heparin analogs, sodium chondroitin sulfate, collagen, elastin, keratin, chitin, and high molecular weight compounds such as chitosan; amino acids such as glycine, aspartic acid, and arginine; sodium lactate, and pyrrolidone carboxylics. Natural moisturizing factors such as sodium acid; lipids such as ceramide, cholesterol, and phospholipids; and plant extracts such as chamomile extract, hamamelis extract, cha extract, and perilla extract.

Examples of antibacterial or bactericidal components include chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, sulfur, resorcin, ethanol, benzethonium chloride, adaparene, benzoyl peroxide, clindamycin, cresol, gluconic acid and its derivatives, povidone iodine, and iodine. Potassium chloride, iodine, isopropylmethylphenol, triclosan, triclosan, photosensitizer 101, photosensitizer 201, paraben, phenoxyethanol, 1,2-pentanediol, alcandiol, glycerin fatty acid ester, alkyldiaminoglycine hydrochloride, chlorhexidine gluconate , Zinc paraphenol sulfonate, azelaic acid and the like.

Examples of vitamins include retinol derivatives such as retinol, retinol acetate, and retinol palmitate, retinal, retinoic acid, methyl retinoate, ethyl retinoate, retinol retinoate, d-δ-tocopheryl retinoate, and α-tocopheryl. Vitamin A such as retinoate and β-tocopheryl retinoate; vitamin E such as dl-α-tocopherol, dl-α-tocopherol acetate, dl-α-tocopherol succinate, and dl-α-tocopherol calcium succinate. Classes; Vitamin B2s such as riboflavin, flavin mononucleotide, flavin adenin dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5'-sodium phosphate, and riboflavin tetranicotinic acid ester; dl-α-tocopherol nicotinate. , Nicotinic acids such as benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, and 1- (4-methylphenyl) ethyl nicotinate; ascorbigen-A, ascorbic acid stearate, ascorbic acid palmitate, and Vitamin Cs such as L-ascorbyl dipalmitate; Vitamin Ds such as methylhesperidine, ergocalciferol, and cholecalciferol; Vitamin Ks such as phylloquinone and farnoquinone; dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine Hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate ester phosphate, thiamine monophosphate, thiamine dilin Vitamin B1s such as acid ester, thiamine diphosphate ester hydrochloride, thiamine triphosphate ester, and thiamine triphosphate monophosphate; pyridoxin hydrochloride, pyridoxin acetate, pyridoxal hydrochloride, 5'-pyridoxal phosphate, and pyridoxamine hydrochloride. Vitamin B6; Vitamin B12 such as cyanocobalamine, hydroxocobalamine, and deoxyadenosylcobalamine; folic acids such as folic acid and pteroylglutamic acid; nicotinic acids such as nicotinic acid and nicotinic acid amide; Pantothenyl alcohol (pantenol), D-pantesin, D-pantetin, supplement Enzyme A and pantothenic acids such as pantothenyl ethyl ether; biotins and biotins such as bioticin; ascorbic acid, sodium ascorbic acid, dehydroascorbic acid, sodium ascorbic acid phosphate, and ascorbic acid such as magnesium ascorbic acid phosphate. Vitamin Cs such as acid derivatives; as well as vitamin-like acting factors such as carnitine, ferulic acid, α-lipoic acid, ollotic acid, γ-orizanol and the like.

Examples of the peptide or its derivative include keratin-degrading peptide, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptide, collagen-degrading peptide, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, and elastin. Degrading Peptide, Conchiolin Degrading Peptide, Hydrolyzed Conchiolin, Silk Proteolytic Peptide, Hydrolyzed Silk, Lauroyl Hydrolyzed Silk Sodium, Soy Proteolytic Peptide, Hydrolyzed Soy Protein, Wheat Protein, Wheat Proteolytic Peptide, Hydrolyzed Wheat Protein, Casein Degrading peptides and acylated peptides (palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl tetrapeptide, etc.) and the like can be mentioned.

Derivatives of amino acids include, for example, betaine (trimethylglycine), carnitine, carnosine and the like.

Examples of the cell activating component include amino acids such as γ-aminobutyric acid and ε-aminoproic acid; vitamins such as retinol, thiamine, riboflavin, pyridoxin hydrochloride, and pantothenic acids; α- such as glycolic acid and lactic acid. Hydrochlorides; tannins, flavonoids, saponins, allantin, photosensitizer No. 301 and the like.
Examples of the anti-aging component include pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivatives, silicon, silicic acid, N-methyl-L-serine, and mevalonolactone.

Examples of blood circulation promoting components include plants (eg, Panax ginseng, Ashitaba, Arnica, Ginkgo, Uikyo, Enmeisou, Dutch oak, Chamomile, Roman chamomile, Carrot, Gentiana, Gobo, Rice, Hawthorn, Shiitake, Seiyousanzashi, Yuzu, Yuzu, etc. Senkyu, Senburi, Thyme, Chow, Chinpi, Touki, Tounin, Touhi, Carrot, Garlic, Butcher Bloom, Grape, Button, Maronnier, Melissa, Yuzu, Yokuinin, Rosemary, Rosehip, Chimpi, Touki, Touhi, Peach, Annes , Walnut, and corn); as well as glucosyl hesperidin and the like.

Examples of the keratin softening component include salicylic acid, glycolic acid, fruit acid, phytic acid, and sulfur.
Examples of the whitening ingredient include ascorbic acid and its derivatives, arbutin, tocopherol, tranexamic acid and the like.
Examples of the astringent component include zinc paraphenol sulfonate, zinc oxide, menthol, ethanol and the like.
Examples of the ultraviolet protective component include 2-ethylhexyl paramethoxysilicate, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester, and 2,4,6-tris [4- (2-ethylhexyl). Oxycarbonyl) anilino] -1,3,5-triazine, t-butylmethoxydibenzoylmethane, dibenzilidendioxoimidazolidine ethylhexyl propyroate, etruhexyltriazoline, paraaminobenzoic acid and its derivatives, paradimethylaminobenzoic acid Examples thereof include octyl, ethylene glycol satylate, dihydroxybenzophenone, titanium oxide, and zinc oxide.

Other active ingredients (physiologically active ingredients or pharmacologically active ingredients) may be used alone or in combination of two or more.

Method of Use The method of using the external composition for skin of the present invention varies depending on the condition, age, gender, etc. of the skin to be used, but for example, the following method may be used. That is, an appropriate amount (for example, about 0.05 to 1 g) may be applied to the skin several times a day (for example, about 1 to 5 times, preferably 1 to 3 times). Further, the daily usage amount of urea is, for example, about 0.005 to 0.1 g, and the daily usage amount of the anti-inflammatory agent is, for example, about 0.001 to 0.01 g. Alternatively, if the composition is applied (coating, spraying, pasting, contact with a bathing agent, etc.) so that the daily amount of amino acids and / or alkanolamines used is, for example, about 0.001 to 0.01 g. good. It is effective and particularly preferable to apply it to the skin after bathing, which softens the keratin.
The application period may be, for example, several days (for example, about 3 days) to about 3 months, preferably about 1 week to 1 month.

The external composition for skin of the present invention is suitable for application by a method such as application, spraying, or sticking to the outer side of the upper arm (upper arm). And for the prevention, amelioration, or treatment of keratin softening on the outside of the upper arm, especially for keratosis pilaris, or for the prevention, amelioration, or treatment of rough, puffy, or muffled symptoms on the outside of the upper arm. It can be suitably used for people with these symptoms.

Others In the present invention, by adding an anti-inflammatory agent to a composition containing urea and amino acids and / or alkanolamines, the keratin softening effect on the outer side of the upper arm of this composition, particularly for keratosis pilaris. Includes methods for enhancing ameliorating effects. Further, the present invention is a method for enhancing the effect of increasing the amount of keratin water on the outside of the upper arm of the composition by adding an anti-inflammatory agent to the composition containing urea and amino acids and / or alkanolamines. Including.
The type, content, pH of the composition, properties of the composition, etc. of each component are the same as those of the external composition for skin of the present invention described above.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
(1) Evaluation of keratin water content of healthy skin First, the outer upper arm and heel of a subject having healthy skin in the 30s to 50s were washed and acclimatized for 10 minutes. Next, the keratin water content of the outer part of the upper arm and the heel of each subject was measured using SKICON-200EX (manufactured by IBS Co., Ltd.) according to the instruction manual attached to this device (initial value).
Then, 10 mg of each test product whose composition is shown in Table 1 below was applied to the outer side of the upper arm and the 2 cm square section of the heel. The keratin water content of the outer part of the upper arm and the heel 30 minutes after application was measured using SKICON-200EX in the same manner as the initial value. The rate of increase in water content at each site was calculated when the initial value was 100%.

The results are shown in FIG.
As is clear from FIG. 1 (B), in the site where keratinization is particularly remarkably advanced and the stratum corneum is thickened, such as the heel, the test preparation of Comparative Example 1 containing urea and glycine (amino acid), or urea and The test preparation of Comparative Example 3 containing dipotassium glycyrrhizinate (anti-inflammatory agent) showed a sufficiently high effect of increasing keratin water content, and the synergistic effect of combining the three components of urea, dipotassium glycyrrhizinate and glycine was observed. It was not recognized at all.
On the other hand, as shown in FIG. 1 (A), when the above three components were applied to the outer side of the upper arm, a synergistically high effect of increasing the amount of keratin water was exhibited, quite unexpectedly.
From this, the external composition for skin of the present invention containing three components of urea, an anti-inflammatory agent and an amino acid is particularly effective in increasing the water content of the outer keratin of the upper arm among the keratin, and is similar to keratosis pilaris. It can be seen that it is useful for the prevention, amelioration, or treatment of keratosis pilaris on the lateral side of the upper arm.

(2) Evaluation of keratosis pilaris in keratosis pilaris The part (affected part) of a subject in the 20s who has keratosis pilaris on the lateral side of the upper arm is washed and acclimatized for 10 minutes. bottom. Next, the amount of water in the stratum corneum of the affected area showing the symptoms of keratosis pilaris is (i) SKICON-200EX (manufactured by IBS Co., Ltd.) and (ii) water to a deeper depth of about 15 μm in the back of the skin. It was measured using each Corneometer (manufactured by Integral Co., Ltd.) that can measure the amount (initial value).
Then, each test preparation shown in Table 1 was applied to the affected area in an appropriate amount (about 0.5 g) twice a day for one week. One week later, the affected area on the lateral side of the upper arm showing keratosis pilaris was marked with a 2 cm square section, and the water content was measured using the devices (i) and (ii) in the same manner as the initial value measurement. bottom. With the initial value as 100%, the rate of increase (%) in the amount of water in the affected area after application for one week was calculated.

The results are shown in FIG. As is clear from FIGS. 2 (A) and 2 (B), the external composition for skin of the present invention containing the three components of urea, an anti-inflammatory agent and glycine is actually applied to keratosis pilaris for one week. Increased keratin water. In addition, a synergistic effect was observed by combining the three components. Therefore, it can be seen that the external composition for skin of the present invention is very useful for improving keratosis pilaris and other keratosis symptoms on the lateral side of the upper arm.
In this test example, each test preparation was continuously applied to the outer part of the upper arm relatively close to the sense of smell (nose), but the example preparation of the present invention generates an ammonia odor peculiar to the urea-containing preparation. It was highly evaluated as a good preparation that was suppressed and had less discomfort.

(3) Evaluation of keratin water content of healthy skin First, the outer upper arm and knee of a subject having healthy skin in the 30s to 50s were washed and acclimatized for 10 minutes. Next, the water content of the keratin on the outer side of the upper arm and the knee of each subject was measured using SKICON-200EX (manufactured by IBS Co., Ltd.) according to the instruction manual attached to this device (initial value).
Then, each test product whose composition is shown in Table 2 below was applied to the lateral part of the upper arm and the 2 cm square section of the knee by 10 mg each in the morning and evening for 3 days. On the day of completion of application, the lateral part of the upper arm and knee of the subject were washed and acclimatized for 10 minutes. The keratin water content of the lateral part of the upper arm and the knee after acclimatization was measured using SKICON-200EX in the same manner as the initial value. The rate of increase in water content at each site was calculated when the initial value was 100%.

The results are shown in FIG.
As is clear from FIG. 3 (B), urea, dipotassium glycyrrhizinate (anti-inflammatory agent), and diisopropanolamine (alkanolamine) are found in the knee, which is a site where keratinization is remarkably advanced and the stratum corneum is thickened as in the heel. No synergistic effect was observed by combining the three components of.
On the other hand, as shown in FIG. 3 (A), when the above three components are applied to the outer part of the upper arm, they are synergistic as in the above-mentioned "(1) Evaluation of keratin water content of healthy skin". It was confirmed that a high keratin water content increasing effect was exhibited.

(4) Evaluation of keratin water content of healthy skin First, the outer part of the upper arm and the knee of a subject having healthy skin in the 30s were washed and acclimatized for 10 minutes. Next, the water content of the keratin on the outer side of the upper arm and the knee of each subject was measured using SKICON-200EX (manufactured by IBS Co., Ltd.) according to the instruction manual attached to this device (initial value).
Then, 10 mg of each test product whose composition is shown in Table 3 below was applied to the outer side of the upper arm and the 2 cm square section of the knee. The amount of water in the outer part of the upper arm and the keratin of the knee 30 minutes after application was measured using SKICON-200EX in the same manner as the initial value. The rate of increase in water content at each site was calculated when the initial value was 100%.

The results are shown in FIG.
As is clear from FIG. 4 (B), in the knee where keratinization is remarkably advanced and the stratum corneum is thickened, the synergistic effect of combining the three components of urea, allantoin (anti-inflammatory agent) and glycine (amino acid) Was not recognized at all.
On the other hand, as shown in FIG. 4 (A), when the above three components are applied to the outer part of the upper arm, the above-mentioned "(1) Evaluation of keratin water content of healthy skin" and "(3) Evaluation of healthy skin" Similar to the result in "Evaluation of keratin water content", it was confirmed that a synergistically high effect of increasing keratin water content was exhibited.

(5) Evaluation and replica analysis of keratosis pilaris in keratosis pilaris The symptomatic part (affected part) of keratosis pilaris in a subject in the 20s who has keratosis pilaris on the lateral side of the upper arm is washed and 10 Acclimated for minutes. Next, the water content of the stratum corneum of the affected area showing the symptoms of keratosis pilaris was measured using (i) SKICON-200EX (manufactured by IBS Co., Ltd.) (initial keratin water content). Separately, a replica of the affected area showing symptoms of keratosis pilaris (replica in the initial state) was collected using SILFLO (manufactured by Amic Group Co., Ltd.).
Then, the test preparations of Examples 2 and 3 whose compositions are shown in Tables 2 and 3 were applied to the affected area twice a day in an appropriate amount (about 0.5 g) for 5 days.
Five days after the start of application, the affected area on the lateral side of the upper arm showing the symptoms of keratosis pilaris was marked with a 2 cm square section, and the water content was measured using the device (i) in the same manner as the measurement of the initial keratin water level. bottom. The rate of increase (%) in the amount of water in the affected area after application for 5 days was calculated with the initial keratin water value as 100%.

Similarly, 5 days after the start of application of the drug, a replica of the affected area on the lateral side of the upper arm showing the symptoms of keratosis pilaris was collected by SILFLO in the same manner as before the start of the test. For the analysis of the collected replicas, a non-contact 3D analysis system PRIMOS (manufactured by GFM) was used in the ridge measurement mode, and the volume (mm ³ ) of 20 ridges was measured for each arm. The reduction rate (%) of the average volume of each ridge in the replica collected from the affected area after application for 5 days was calculated, assuming that the average volume of each ridge in the replica in the initial state before the start of the test was 100%.

The evaluation result of the keratin water content is shown in FIG. As is clear from FIG. 5, (A) urea, (B) an anti-inflammatory agent, and (C) are the same as the test results of Example 1 in the above-mentioned "(2) Evaluation of keratin water content in keratosis pilaris". ) It was confirmed that the external composition for skin of the present invention containing three components of an amino acid and / or an alkanolamine increases keratin water when applied to keratosis pilaris for 5 days.
Further, the evaluation result of the replica analysis is shown in FIG. As is clear from the results of FIG. 6, by using the external composition for skin containing the three components (A) to (C) of the present invention, the volume of the ridge of the affected area exhibiting the symptom of keratosis pilaris is reduced. However, it was confirmed that it was possible to effectively improve the lumpy, lumpy, and rough symptoms of the affected area.
Therefore, it can be seen that the external composition for skin of the present invention is very useful for improving keratosis pilaris and other keratosis symptoms on the lateral side of the upper arm.

(6) Evaluation of keratin water content of healthy skin First, the outer upper arm and knee of a subject having healthy skin in the 30s to 50s were washed and acclimatized for 10 minutes. Next, the water content of the keratin on the outer side of the upper arm and the knee of each subject was measured using SKICON-200EX (manufactured by IBS Co., Ltd.) according to the instruction manual attached to this device (initial value).
Then, 10 mg of each test product whose composition is shown in Table 4 below was applied to the outer side of the upper arm and the 2 cm square section of the knee. The amount of water in the outer part of the upper arm and the keratin of the knee 30 minutes after application was measured using SKICON-200EX in the same manner as the initial value. The rate of increase in water content at each site was calculated when the initial value was 100%.

The results are shown in FIG.
As is clear from FIG. 7B, in the knee where keratinization is remarkably advanced and the stratum corneum is thickened, three components of urea, monoammonium glycyrrhizinate (anti-inflammatory agent) and triethanolamine (alkanolamine) are used. No synergistic effect was observed by the combination of.
On the other hand, as shown in FIG. 7 (A), when the above three components are applied to the outer part of the upper arm, the above-mentioned "(1) Evaluation of keratin water content of healthy skin" and "(3) Evaluation of healthy skin" Similar to the results in "Evaluation of keratin water content" and "(4) Evaluation of keratin water content of healthy skin", it was confirmed that a synergistically high effect of increasing keratin water content was exhibited.

(7) Evaluation of keratin water content of healthy skin First, the outer upper arm and knee of a subject having healthy skin in the 30s to 50s were washed and acclimatized for 10 minutes. Next, the water content of the keratin on the outer side of the upper arm and the knee of each subject was measured using SKICON-200EX (manufactured by IBS Co., Ltd.) according to the instruction manual attached to this device (initial value).
Then, each test preparation shown in Table 5 below was applied to the lateral part of the upper arm and the 2 cm square section of the knee in an amount of 10 mg each in the morning and evening for 4 days. On the day of completion of application, the lateral part of the upper arm and knee of the subject were washed and acclimatized for 10 minutes. The keratin water content of the lateral part of the upper arm and the knee after acclimatization was measured using SKICON-200EX in the same manner as the initial value. The rate of increase in water content at each site was calculated when the initial value was 100%.

The results are shown in FIG.
As is clear from FIG. 8 (B), urea, monoammonium glycyrrhizinate (anti-inflammatory agent), and triethanolamine (alkanolamine) are found in the knees where keratinization is remarkably advanced and the stratum corneum is thickened even when used continuously. No synergistic effect was observed by combining the three components with).
On the other hand, as shown in FIG. 8 (A), when the above three components are continuously applied to the outer part of the upper arm, the above-mentioned "(1) Evaluation of keratin water content of healthy skin" and "(3) Similar to the results in "Evaluation of keratin water content of healthy skin", "(4) Evaluation of keratin water content of healthy skin", and "(6) Evaluation of keratin water content of healthy skin", synergistically high keratin water content It was confirmed that the effect of increasing the amount was exhibited.

(8) Evaluation and replica analysis of keratosis pilaris in keratosis pilaris The symptomatic part (affected part) of keratosis pilaris in a subject in the 20s who has keratosis pilaris on the lateral side of the upper arm is washed and 10 Acclimated for minutes. Next, the water content of the stratum corneum of the affected area showing the symptoms of keratosis pilaris was measured using (i) SKICON-200EX (manufactured by IBS Co., Ltd.) (initial keratin water content). Separately, a replica of the affected area showing symptoms of keratosis pilaris (replica in the initial state) was collected using SILFLO (manufactured by Amic Group Co., Ltd.).
Then, the test preparation of Example 5 whose composition is shown in Table 5 was applied to the affected area twice a day in an appropriate amount (about 0.5 g) for 4 days.
Four days after the start of application, a 2 cm square section was marked on the affected area on the lateral side of the upper arm showing keratosis pilaris, and the water content was measured using the device (i) in the same manner as the measurement of the initial keratin water level. bottom. The rate of increase (%) in the amount of water in the affected area after application for 4 days was calculated with the initial keratin water value as 100%.

Similarly, 4 days after the start of application of the drug, a replica of the affected area on the lateral side of the upper arm showing the symptoms of keratosis pilaris was collected by SILFLO in the same manner as before the start of the test. For the analysis of the collected replicas, a non-contact 3D analysis system PRIMOS (manufactured by GFM) was used in the ridge measurement mode, and the volume (mm ³ ) of 20 ridges was measured for each arm. The reduction rate (%) of the average volume of each ridge in the replica collected from the affected area after application for 4 days was calculated, assuming that the average volume of each ridge in the replica in the initial state before the start of the test was 100%.

The evaluation result of the keratin water content is shown in FIG. As is clear from FIG. 9, (A) urea, (B) anti-inflammatory agent and (C) amino acid are similar to the results in the evaluation of keratin water content in keratosis pilaris described above (2) and (5). It was confirmed that the external composition for skin of the present invention containing three components with and / or alkanolamine increased keratin water when applied to keratosis pilaris for 4 days.
Further, the evaluation result of the replica analysis is shown in FIG. As is clear from the results of FIG. 10, by using the external composition for skin containing the three components (A) to (C) of the present invention, the volume of the ridge of the affected area exhibiting the symptom of keratosis pilaris is reduced. However, it was confirmed that it was possible to effectively improve the lumpy, lumpy, and rough symptoms of the affected area.
Therefore, it can be seen that the external composition for skin of the present invention is very useful for improving keratosis pilaris and other keratosis symptoms on the lateral side of the upper arm.

An example of formulation of the external composition of the present invention is shown below.
<Formulation example 1 Cream (oil-in-water type)>
(1) Ion-exchanged water residue (2) Urea 10% by weight
(3) Glycerin 10% by weight
(4) 1,3-butylene glycol 5% by weight
(5) Dipotassium glycyrrhizinate 1.0% by weight
(6) Paraben 0.2% by weight
(7) Trisodium edetate 0.05% by weight
(8) Carboxyvinyl polymer 0.4% by weight
(9) Triethanolamine 0.5% by weight
(10) Polyoxyethylene hydrogenated castor oil 0.5% by weight
(11) Sorbitan monostearate 0.5% by weight
(12) Glycine 1.0% by weight
(13) Liquid paraffin 10% by weight
(14) Isopropyl palmitate 5.0% by weight
(15) Cetanol 5.0% by weight

<Formulation example 2 Cream (oil-in-water type)>
(1) Ion-exchanged water residue (2) Urea 20% by weight
(3) Glycerin 5% by weight
(4) 1,3-butylene glycol 5% by weight
(5) Dipotassium glycyrrhizinate 0.5% by weight
(6) Paraben 0.2% by weight
(7) Trisodium edetate 0.05% by weight
(8) Carboxyvinyl polymer 0.3% by weight
(9) Triethanolamine 0.5% by weight
(10) Polysorbate 60 2.5% by weight
(11) Sorbitan monostearate 1.5% by weight
(12) Glycine 0.5% by weight
(13) Liquid paraffin 5% by weight
(14) Isopropyl palmitate 3% by weight
(15) Stearyl alcohol 2% by weight

<Formulation example 3 gel agent>
(1) Ion-exchanged water residue (2) Glycerin 15% by weight
(3) 1,3-butylene glycol 5% by weight
(4) Xanthan gum 0.8% by weight
(5) Paraben 0.2% by weight
(6) Trisodium edetate 0.1% by weight
(7) Carboxyvinyl polymer 0.2% by weight
(8) Dimethylpolysiloxane 0.5% by weight
(9) Triethanolamine 0.3% by weight
(10) Glycine 1.0% by weight
(11) DL-alanine 1% by weight
(12) Urea 10% by weight
(13) Dipotassium glycyrrhizinate 0.5% by weight

The composition of the present invention has a high commercial value because it is highly effective in improving the keratinization of the outer side of the upper arm, which has few effective medicines.

Claims (1)

External composition for application to the lateral part of the upper arm containing at least one selected from the group consisting of (A) urea, (B) anti-inflammatory agent, and (C) amino acid, alkanolamine, and salts thereof. (However, except when it is a pharmaceutical composition).

Images